3.4900 0.00 (0.00%)
After hours: 5:00PM EDT
|Bid||3.4900 x 4000|
|Ask||3.5000 x 4000|
|Day's Range||3.4800 - 3.6100|
|52 Week Range||2.2500 - 3.8900|
|Beta (3Y Monthly)||0.30|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 7, 2019 - May 13, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.00|
Emergent (EBS) posts interim data from the phase II study on its chikungunya vaccine, CHIKV-VLP. The candidate generates positive immune response against the chikungunya virus.
Kamada (KMDA) wins the FDA acceptance for the path forward regarding its inhaled Alpha-1-Antitrypsin product, currently under development for treating Alpha-1 Antitrypsin Deficiency.
INCLINE VILLAGE, Nev. , April 16, 2019 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that the Company will hold its annual meeting of stockholders on Thursday, ...
Axsome's (AXSM) mid-stage candidate, AXS-05, achieves the primary endpoint in a phase II study as a smoking cessation treatment. Shares rise.
Fibrocell (FCSC) collaborates with Castle Creek to develop/commercialize its gene therapy candidate, FCX-007, for the rare skin disease of recessive dystrophic epidermolysis bullosa. Stock jumps.
Mallinckrodt (MNK) ends enrollment in the phase III study on StrataGraft, a regenerative skin tissue used in patients with thermal burns.
PDL BioPharma (PDLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
INCLINE VILLAGE, Nev., April 11, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (PDLI) announces that it has entered into a securities purchase agreement with Evofem Biosciences, Inc. ("Evofem") (EVFM), pursuant to which it will invest a total of up to $60 million in a private placement of securities. The transaction is expected to have two tranches. The first tranche comprises $30 million, which was provided today. In addition, PDL has the right to invest an additional $30 million in a second tranche alongside two existing Evofem shareholders, which have the right to invest up to $10 million each.
"Successful completion of this financing should enable us to execute our strategy with confidence and to ensure the successful launch of Amphora in 2020 as a novel, hormone-free, woman-controlled contraceptive, if approved by the FDA," said Saundra Pelletier, CEO of Evofem Biosciences.
Acorda (ACOR) aims to boost sales with the launch of its newly FDA-approved Parkinson's disease drug, Inbrija. The company's pipeline looks promising as well.
Inovio (INO) receives the third milestone payment from AstraZeneca post the initiation of dosing in a phase II combo study of the latter's MEDI0457 for HPV related anal, penile and vulvar cancers.
Puma Biotech (PBYI) increases cohorts in the phase II SUMMIT basket study on Nerlynx for cancer patients suffering tumors with activating EGFR or HER2 mutations.
[Editor's note: This story was previously published in May 2018. It has since been updated and republished.]Do you think penny stocks are best left to amateur traders who don't understand that cheap stocks are cheap for a reason? It's not an entirely unfair assessment. Many of these young (and doomed) companies are the beneficiaries of great sales pitches, but their investors often end up suffering buyer's remorse.It's a misnomer, however, to think that all penny stocks -- let's quantify them as equities priced at less than $5 per share -- aren't worth owning. Thanks to factors ranging from prolonged weakness in the commodities market to strategic stock splits to poorly-timed IPOs, a handful of these low-priced equities are actually compelling prospects.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 15 Stocks to Buy Leading the Financial Charge Here's a run-down of four of the best penny stocks to mull for 2019, and maybe beyond. All of these names are listed on exchanges. AK Steel Holding Corporation (AKS)One would think the steel business is steady and predictable, with these stocks (and steel prices) ebbing and flowing more or less with the macro economic cycle. That conclusaion isn't correct, however.The steel industry is a volatile mess, with ever-changing supply and demand making it impossible for the likes of AK Steel Holding Corporation (NYSE:AKS) to commit to a plan for the future.As a result, AKS stock has basically gone nowhere for the past 15 years, with everything that could go wrong during that time for AKS going wrong at an inopportune time.That may finally be on the verge of changing, however. With President Trump at least willing to try to level the playing field between the United States' steel companies and overseas rivals at the same time the global economy appears to be picking up some steam, AK Steel is in a proverbial sweet spot. PDL BioPharma Inc (PDLI)PDL BioPharma (NASDAQ:PDLI) is a curious beast. It was initially established as a vehicle to acquire the rights to, or patents on, highly marketable drugs that would ultimately drive income for its investors.It worked too, for a while. As time marched on, however, drug developers realized they could do for themselves what PDL was doing. Ergo, PDL BioPharma has been struggling for a while now to acquire drugs and marketing rights at prices that left room for healthy dividends.That's a big part of the reason PDLI stock has fallen from a value of more than $30 in 2006 to a price of only $3.77 per share now. * 15 Stocks to Buy Leading the Financial Charge Groupon Inc (GRPN)Talk about a fall from grace! Groupon (NASDAQ:GRPN) was a market darling when it went public back in 2011, at a price of $28 per share. It had a honeymoon that didn't last long at all though, with shares retreating into penny-stock territory less than a year later, where it's been stuck ever since.And truth be told, Groupon stock deserved the beating it took. Not only was its pre-IPO growth rate not built to last, but a host of competition has stepped up to the plate in the meantime. Its net income peaked in 2012, and its sales peaked in 2015.The daily-deals company may have finally found a winning formula though, setting the stage for improvement in 2019 and beyond.Analysts say that while sales are apt to fall this year, its EPS should rise. That may be all traders need to see to get this stock back in a nice uptrend. Zynga Inc (ZNGA) Note: Zynga stock has risen slightly above $5 since this column was first published.Last but not least, put Zynga (NASDAQ:ZNGA) on your list of penny stocks to mull for 2019. Yes, this is the same Zynga behind great online games like Words With Friends, FarmVille and several other titles you may not have realized were part of its library.This is the same Zynga that Facebook dropped an exclusivity arrangement with back in 2012, undermining its well-received IPO from 2011 and sending the stock to a sub-$5 price where it's been almost ever since. Though Zynga hasn't done poorly, it's certainly not done nearly as well as investors were expecting it to when it first IPO'd. * 15 Stocks to Buy Leading the Financial Charge Change is brewing though. In 2017, CEO and founder Mark Pincus gave up his control of the company by scrapping the two classes of voting shares that granted him an inordinate degree of voting power.That's not to say he alone was the reason the company was unable to grow in a meaningful way, but it certainly didn't help. In the meantime, its revenue and income are expected to edge higher this year, anyway.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can follow him on Twitter, at @jbrumley. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Stocks From Around the World That Beat U.S. Stocks * 7 Breakout Stocks to Watch in 2019 * 5 Cheap Small-Cap Stocks to Buy Compare Brokers The post 4 Penny Stocks to Own for 2019 appeared first on InvestorPlace.
Puma Biotech (PBYI) out-licenses development and marketing rights to its breast cancer drug Nerlynx to Pierre Fabre in Europe and across some African countries. Shares fall.
Agios' (AGIO) first wholly owned precision medicine, Tibsovo, has been picking up the sales pace since its FDA approval last year with strong sequential growth delivered in Q4.
Agios (AGIO) receives a Breakthrough Therapy designation for Tibsovo combo to treat the newly diagnosed acute myeloid leukemia in adult patients with an IDH1 mutation.
INCLINE VILLAGE, Nev. , March 26, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that Dominique Monnet , PDL's president and chief executive ...
PDL BioPharma's (PDLI) earnings exceed estimates in Q4. Lower royalties as well as weak product sales induce a downfall in year-over-year revenues.
The Incline Village, Nevada-based company said it had net income of 11 cents per share. Earnings, adjusted for one-time gains and costs, came to 10 cents per share. The biotechnology company posted revenue ...
INCLINE VILLAGE, Nev. , March 14, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) reports financial results for the three and 12 months ended December ...